StockData
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. (LRMR) stock

LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$2.99−0.01 (-0.33%)

Close on Nov 17, 2026Market cap $310.61MP/E –Yield –

Larimar Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Larimar Therapeutics's operating cash flow for the twelve months ending Jun 30, 2025 was -$92.28M. For fiscal 2025 it was -$113.20M. The highest annual figure on record is -$13.59M in fiscal 2012.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$113.20M–
FY2024Dec 31, 2024-$70.76M–
FY2023Dec 31, 2023-$33.46M–
FY2022Dec 31, 2022-$27.57M–
FY2021Dec 31, 2021-$42.11M–
FY2020Dec 31, 2020-$42.20M–
FY2019Dec 31, 2019-$22.70M–
FY2018Dec 31, 2018-$51.49M–
FY2017Dec 31, 2017-$43.78M–
FY2016Dec 31, 2016-$51.98M–
FY2015Dec 31, 2015-$59.55M–
FY2014Dec 31, 2014-$28.24M–
FY2013Dec 31, 2013-$15.00M–
FY2012Dec 31, 2012-$13.59M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$44.03M–
Q1 FY2026Mar 31, 2026-$44.61M–
Q2 FY2025Jun 30, 2025-$19.38M–
Q1 FY2025Mar 31, 2025-$26.54M–
Q4 FY2024Dec 31, 2024-$21.82M–
Q3 FY2024Sep 30, 2024-$24.55M–
Q2 FY2024Jun 30, 2024-$13.99M–
Q1 FY2024Mar 31, 2024-$10.41M–
Q4 FY2023Dec 31, 2023-$9.34M–
Q3 FY2023Sep 30, 2023-$9.20M–
Q2 FY2023Jun 30, 2023-$7.37M–
Q1 FY2023Mar 31, 2023-$7.55M–
Q4 FY2022Dec 31, 2022-$6.67M–
Q3 FY2022Sep 30, 2022-$5.88M–
Q2 FY2022Jun 30, 2022-$7.49M–
Q1 FY2022Mar 31, 2022-$7.53M–
Q4 FY2021Dec 31, 2021-$7.92M–
Q3 FY2021Sep 30, 2021-$12.20M–
Q2 FY2021Jun 30, 2021-$10.78M–
Q1 FY2021Mar 31, 2021-$11.21M–
Q4 FY2020Dec 31, 2020-$9.86M–
Q3 FY2020Sep 30, 2020-$11.22M–
Q2 FY2020Jun 30, 2020-$12.20M-447.9%
Q1 FY2020Mar 31, 2020-$8.92M–
Q4 FY2019Dec 31, 2019-$7.91M–
Q3 FY2019Sep 30, 2019-$5.82M–
Q2 FY2019Jun 30, 2019$3.51M–
Q1 FY2019Mar 31, 2019-$12.47M–
Q4 FY2018Dec 31, 2018-$11.83M–
Q3 FY2018Sep 30, 2018-$13.08M–
Q2 FY2018Jun 30, 2018-$13.31M–
Q1 FY2018Mar 31, 2018-$13.27M–
Q4 FY2017Dec 31, 2017-$9.84M–
Q3 FY2017Sep 30, 2017-$12.09M–
Q2 FY2017Jun 30, 2017-$10.18M–
Q1 FY2017Mar 31, 2017-$11.68M–
Q4 FY2016Dec 31, 2016-$8.67M–
Q3 FY2016Sep 30, 2016-$11.03M–

More Larimar Therapeutics figures

See a number that looks wrong?